Stock ACXP ACURX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Delayed Nasdaq
Other stock markets
 10:49:19 2024-04-30 am EDT 		5-day change 1st Jan Change
2.14 USD -2.28% Intraday chart for Acurx Pharmaceuticals, Inc. +4.90% -44.13%
Apr. 04 Top Premarket Gainers MT
Mar. 19 H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating MT

Evolution of the average Target Price on Acurx Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

00e39e042ed246c3e5f918d33afdf.PO3hVGnuP_rNL9t9QAJb8MZcqbaI9lYZPFzES5aqYm4.C4K1bCumas6vZIwTLXcokqkZwvXrvh1bUjSQBczgIQgKhNRjAKdWn4l_mg~21a404973865c3c6a89a147aa0797179

Analyst Recommendations on Acurx Pharmaceuticals, Inc.

H.C. Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $12 From $14, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $14 From $13, Keeps Buy Rating MT
Acurx Reports 96% Clinical Cure Rate in Phase 2 Trial of Ibezapolstat in C. Difficile Infection; Shares Fall MT
Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection CI
Maxim Raises Price Target on Acurx Pharmaceuticals to $10 From $7, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Acurx Pharmaceuticals to $13 From $14, Keeps Buy Rating MT
HC Wainwright Initiates Acurx Pharmaceuticals With Buy Rating, Sets $14 Price Target MT
Alliance Global Starts Acurx Pharmaceuticals at Buy With $14 Price Target MT
Maxim Group Starts Acurx Pharmaceuticals at Buy With $12 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.19 USD
Average target price
11.45 USD
Spread / Average Target
+422.83%
High Price Target
12.35 USD
Spread / Highest target
+463.93%
Low Price Target
10 USD
Spread / Lowest Target
+356.62%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Acurx Pharmaceuticals, Inc.

HC Wainwright
Maxim
Alliance Global Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ACXP Stock
  4. Consensus Acurx Pharmaceuticals, Inc.